IntoCell, Inc. (KOSDAQ:287840)
South Korea · Delayed Price · Currency is KRW 50,800
+100 (0.20%)
At close: Feb 27, 2026
IntoCell Revenue
IntoCell had revenue of 1.42B KRW in the quarter ending September 30, 2025, with 44.41% growth. This brings the company's revenue in the last twelve months to 1.68B, down -39.84% year-over-year. In the year 2024, IntoCell had annual revenue of 2.91B with 79.72% growth.
Revenue (ttm)
1.68B
Revenue Growth
-39.84%
P/S Ratio
452.99
Revenue / Employee
n/a
Employees
n/a
Market Cap
762.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.91B | 1.29B | 79.72% |
| Dec 31, 2023 | 1.62B | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 140.03M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 100.17B |
| NIBEC | 32.96B |
| ROKIT Healthcare | 20.33B |
| S.Biomedics | 16.96B |
| JS Link | 16.14B |
| AprilBio | 8.97B |
| Qurient | 8.28B |
| Y-Biologics | 3.61B |